NCT01011075已完成2 期
A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 3
- 主要终点
- Response Rate
研究概览
简要总结
This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.
详细描述
Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Imatinib 600 mg/day, oral administration in 4-day pulses bracketing each paclitaxel infusion (days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 70 years
- •Histologic or cytologic diagnosis of non-small cell lung cancer
- •At least one site of measurable disease, as defined by the modified RECIST criteria (See section 7.6)
- •Stage IIIB with pleural effusion or Stage IV disease. Includes patients who received surgery alone for early stage disease, now in relapse with advanced disease. Staging is according to the American Joint Committee on Cancer classification scheme, 6th edition.48
- •Adequate hepatic, renal and marrow function
- •Liver function tests: total bilirubin < 1.25 x upper limit of normal (ULN), AST and ALT < 2.5 x ULN, Creatinine < 1.5 x ULN
- •Baseline absolute neutrophil count > 1500/μL
- •Baseline platelet count > 100,000/μL
- •ECOG Performance Status 0, 1 or 2 at the time of informed consent. (See Appendix 1)
- •Written, voluntary consent
- •Patients with reproductive potential must use an acceptable contraceptive method. Such methods include: 1) Male hormonal contraception; 2) Partner without reproductive potential, including post-menopausal status or history of tubal ligation; 3) Partner with intrauterine device (IUD) or contraceptive vaginal ring; 4) Partner takes oral contraceptive pill, wears contraceptive patch, or has contraceptive implant; 5) Routine use of barrier method, such as condoms or diaphragm, during sexual intercourse.
排除标准
- •Uncontrolled brain metastasis. Patients with known brain metastasis must have completed treatment with surgery, radiation or both. In addition, they must be off corticosteroids.
- •Symptomatic neuropathy (Grade 2 or higher)
- •Prior chemotherapy for advanced non-small cell lung cancer. (Prior adjuvant, neoadjuvant, or chemoradiotherapy for NSCLC is permitted, provided at least 6 months elapsed prior to documented metastatic recurrence.)
- •Patient is < 5 years free of another primary malignancy, except: a) if the other malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other primary malignancy is not considered clinically significant and is requiring no active intervention
- •Prior radiation therapy to > 25% of bone marrow
- •Grade III/IV congestive heart failure, as defined by NYHA criteria, or myocardial infarction within 6 months.
- •Any serious or uncontrolled concomitant disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
- •Patient has known chronic liver disease, e.g. diagnosis of chronic active hepatitis or cirrhosis.
- •Major surgery two weeks prior to study treatment
- •Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent
- •Any condition requiring continuous administration of systemic corticosteroids.
- •The patient is on therapeutic anti-coagulation with warfarin.
研究组 & 干预措施
Imatinib mesylate + Paclitaxel
Experimental
Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses bracketing each paclitaxel infusion (days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
干预措施: Imatinib mesylate (Drug)
Imatinib mesylate + Paclitaxel
Experimental
Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses bracketing each paclitaxel infusion (days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
干预措施: Paclitaxel (Drug)
结局指标
主要结局
Response Rate
时间窗: 6 months
Response rates according to RECIST criteria (version 1.0) expressed as percentage of evaluable patients.
次要结局
- Toxicities(12 months)
- Progression Free Survival(12 months)
- Overall Survival(12 Months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerMalignant Pleural EffusionNCT00408460University of Washington34
终止
2 期
Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric AdenocarcinomaGastric AdenocarcinomaNCT00209079Emory University5
终止
2 期
Safety Study of Gleevec® in Children With Pulmonary HypertensionPulmonary HypertensionNCT00583115Indiana University1
已完成
2 期
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic SyndromesLeukemia, MyeloidMyelodysplastic SyndromesNCT00451997M.D. Anderson Cancer Center10
已完成
2 期
Gleevec Idiopathic Pulmonary Fibrosis (IPF) StudyLung DiseaseIdiopathic Pulmonary FibrosisPulmonary FibrosisNCT00131274Daniels, Craig E., M.D.120